TY - JOUR
KW - cocaine use disorder
KW - Cognitive remediation
KW - Levodopa
KW - Ropinirole
KW - Randomized Clinical Trial
KW - Bayesian mediation
KW - Clinical Trial
KW - Empirical Study
KW - Quantitative Study
KW - Treatment Outcome
KW - Human
KW - Male
KW - Female
KW - Inpatient
KW - Adulthood (18 yrs & older)
KW - Young Adulthood (18-29 yrs)
KW - Thirties (30-39 yrs)
KW - Middle Age (40-64 yrs)
KW - Treatment Outcomes
KW - Bayesian Analysis
KW - Substance use disorder
KW - cocaine
KW - Statistical Probability
KW - Randomized Clinical Trials
KW - dopamine agonists
KW - article
KW - US
KW - 3340:Clinical Psychopharmacology
AU - Joy M. Schmitz
AU - Robert Suchting
AU - Charles E. Green
AU - Heather E. Webber
AU - Jessica Vincent
AU - F. G. Moeller
AU - Scott D. Lane
A1 - 
AD - Faillace Department of Psychiatry and Behavioral Sciences, UTHealth McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, US Joy.M.Schmitz@uth.tmc.edu; Department of Pediatrics, Center for Clinical Research and Evidence-Based Medicine, UTHealth McGovern Medical School, Houston, TX, US ; Virginia Commonwealth University, Richmond, VA, US ; Schmitz, Joy M.,1941 East Road,Houston,US,77054,Center for Neurobehavioral Research on Addiction, Faillace Department of Psychiatry & Behavioral Sciences, McGovern Medical School, University of Texas Health Science Center – Houston,Joy.M.Schmitz@uth.tmc.edu
BT - Drug and alcohol dependence
C5 - Measures; Opioids & Substance Use
DO - 10.1016/j.drugalcdep.2021.108800
JF - Drug and alcohol dependence
LA - English
M1 - Journal Article
PY - 2021
SN - 0376-8716, 0376-8716
SP - 10
T1 - The effects of combination levodopa-ropinirole on cognitive improvement and treatment outcome in individuals with cocaine use disorder: A Bayesian mediation analysis
T2 - Drug and alcohol dependence
TI - The effects of combination levodopa-ropinirole on cognitive improvement and treatment outcome in individuals with cocaine use disorder: A Bayesian mediation analysis
U1 - Measures; Opioids & Substance Use
U3 - 10.1016/j.drugalcdep.2021.108800
VL - 225
VO - 0376-8716, 0376-8716
Y1 - 2021
Y2 - Aug 01
ER -